27 results about "Lactate dehydrogenases" patented technology

The present disclosure relates to a genetically modified microorganism satisfying some of predetermined conditions. The predetermined conditions include: (I) succinate dehydrogenase activity or fumarate reductase activity being reduced or inactivated relative to a wild-type microorganism; (II) lactate dehydrogenase activity being reduced or inactivated relative to the wild-type microorganism; (III) the genetically modified microorganism having modified phosphoenolpyruvate carboxylase activity showing resistance to feedback inhibition by aspartic acid in wild-type phosphoenolpyruvate carboxylase activity, or exogenous phosphoenolpyruvate carboxylase activity having higher resistance to feedback inhibition by aspartic acid than that of the wild-type phosphoenolpyruvate carboxylase activity shown by the wild-type microorganism; and (IV) pyruvate:quinone oxidoreductase being reduced or inactivated relative to the wild-type microorganism.

The application relates to the frontiers of nanomaterials and drug screening fields, and discloses a fluorescent probe material for drug screening and a drug screening method. The fluorescent probe material realizes screening of anticancer drug efficacy of a to-be-detected drug by detecting the concentration of an NAD+ (nicotinamide adenine dinucleotide) active marker of lactate dehydrogenase, the fluorescent probe material comprises an A agent and a B agent, the A agent is a covalent organic framework material loaded with carbon dots with reducibility, and is denoted as COF@CDs, and the B agent is a transition metal hydride; the transition metal hydride can make NAD+ hydrogenated and reduced into NADH in the presence of the COF@CDs; the product after hydrogen loss of the transition metal hydride can be combined with the COF@CDs, and the COF@CDs can emit fluorescence under excitation light, and the fluorescence is quenched.

The invention discloses engineering probiotics for expressing D-lactic dehydrogenase as well as a construction method and application of the engineering probiotics, and belongs to the technical field of biological medicines. The engineering probiotics disclosed by the invention are constructed by taking escherichia coli Nissle 1917 as an original strain and exogenously transferring a coding gene of D-lactic dehydrogenase into the original strain. By means of synthetic biology, a living body treatment factory capable of removing specific metabolites in situ is constructed, and treatment normal form transformation from protein inhibition to metabolite removal is achieved; through a lipid coating technology, oral delivery and intestinal targeted colonization of engineering bacteria are realized, and the treatment accuracy and efficiency are improved; transformation is carried out based on probiotics EcN, so that the biological safety is high; the treatment process is oral administration and is non-invasive, and systemic toxic and side effects of traditional chemotherapy are avoided.

The invention discloses an application of compounds N-(1-naphthyl)-2-phenoxy acetamide and N-(1-naphthyl)-2-(phenylamino) ethyl thioamide in preparation of cryptosporidium resisting medicines, and belongs to the technical field of medicines and veterinary medicines of anti-parasitic medicines. The compound is obtained through functional group modification by taking NSC158011 as a pilot structure and can efficiently inhibit the activity of cryptosporidium parvum lactic dehydrogenase, and the inhibition rates respectively reach 60-70% and gt; 90%. An in-vitro experiment shows that parasite load is obviously reduced in HCT-8 cells by the two; in vivo, in a gamma-interferon gene knockout mouse and calf infection model, the fecal oocyst load is reduced by 40-100 times, the intestinal barrier repair can be promoted, and the safety is good. The invention reveals that the compound has efficient insect-resistant activity, high safety and intestinal protection effect for the first time, and provides important material basis and technical support for developing a new generation of cryptosporidium-resistant drugs.

This invention discloses a lactate reactor capable of inhibiting intervertebral disc degeneration and its preparation method. The lactate reactor is an injectable gel microsphere loaded with lactate-catalyzing nanoparticles and matrix cell-derived factor SDF-1α. The lactate-catalyzing nanoparticles are mesoporous silica nanoparticles, whose mesopores are coated with lactate dehydrogenase, nicotinamide adenine dinucleotide, alanine aminotransferase, and glutamate, and whose surface is coated with an oxidized sodium alginate layer via a Schiff base reaction. This invention can efficiently convert pathological lactate in the nucleus pulposus microenvironment into alanine, which inhibits degeneration, while simultaneously recruiting stem cells to synergistically inhibit the process of intervertebral disc degeneration.

The present invention relates to compositions and methods of use thereof. Methods are drawn towards treating oxalate production-related disease or disorder by inhibiting the activity of glycolate oxidase (GO) and lactate dehydrogenase (LDHA) while activating degradation of GO and / or LDHA.

The application discloses a clinical biochemical composite quality control product, which comprises detection item raw materials, a matrix liquid and a protective agent; the detection item raw materials are alkaline phosphatase, amylase, sodium glycocholate, cholinesterase, creatinine, leucine aminopeptidase, lactate dehydrogenase, lipase, triglyceride, cholesterol, uric acid, urea, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, glucose, alpha-hydroxybutyric acid dehydrogenase, sodium hydrogen phosphate, magnesium chloride, calcium chloride, ferrous chloride, bilirubin, pancreatic amylase and sodium bicarbonate; the matrix liquid is bovine serum albumin and human serum albumin; and the protective agent is dithiothreitol (DTT), mannitol, trehalose, sodium chloride, a composite enzyme stabilizer AES and sodium azide. The quality control product can realize the detection of 27 clinical biochemical items, and the freeze-drying process is adopted, so that the freeze-dried composite quality control product has low viscosity, is easy to be re-dissolved and mixed, has high stability and has small matrix effect.

This invention discloses the application of a flavonoid compound from Citrus aurantium, specifically the application of a flavonoid compound from Citrus aurantium or its physiologically acceptable salt in the preparation of anti-inflammatory and / or therapeutic drugs for diseases related to lactate dehydrogenase release. The flavonoid compound from Citrus aurantium has the structural formula shown in Formula I, wherein R1 is selected from methoxy, hydrogen, ethoxy, or hydroxy; R2 is selected from methoxy, hydrogen, ethoxy, or hydroxy; R3 is selected from methoxy, hydrogen, ethoxy, or hydroxy; R4 is selected from methoxy, hydrogen, ethoxy, or hydroxy; R5 is selected from methoxy, hydrogen, ethoxy, or hydroxy; R6 is selected from methoxy, hydrogen, ethoxy, or hydroxy; and the C2-C3 bond is a double bond or a saturated bond. This invention clarifies that among the flavonoid compounds from Citrus aurantium, isopyroside, apigenin, norihesperidin, hesperidin, and isohesperidin can significantly inhibit LPS-induced LDH release in HL-1 cells and can serve as lead compounds for antiseptic myocardial injury drugs.

This invention discloses the application of primrosein in the preparation of drugs for the treatment of liver fibrosis. The chemical name of primrosein is 2-methoxy-6-pentyl-1,4-benzoquinone, and its molecular formula is C2. 12 O3H 16 Cellular experiments showed that primrosein reduced the proliferative activity of hepatic stellate cells but did not increase the release of lactate dehydrogenase from hepatic stellate cells, and had no significant inhibitory effect on hepatocyte proliferation. Animal experiments showed that primrosein reduced serum levels of markers in carbon tetrachloride-induced liver fibrosis model mice, decreased collagen fiber content in their liver tissue, and inhibited the expression of hepatic stellate cell activation markers, demonstrating excellent anti-liver fibrosis effects. This indicates that primrosein can be used to prepare effective drugs for the treatment of liver fibrosis.

The present application relates to the technical field of bioengineering, and particularly relates to a recombinant Saccharomyces cerevisiae and a construction method and application thereof, comprising the following steps: step one, using the whole genome of Enterococcus faecalis as a template, a recombinant strain SC1-1 is constructed; step two, using the recombinant strain SC1-1 as a primary strain, L-lactate dehydrogenase CYB2 gene of Saccharomyces cerevisiae is knocked out to obtain a recombinant strain SC2; step three, using the recombinant strain SC2 as a primary strain, branched-chain-2-oxo acid decarboxylase THI3 gene of Saccharomyces cerevisiae is knocked out to obtain a recombinant strain SC3; step four, using the whole genome of Saccharomyces cerevisiae as a template, a recombinant strain SC4 is constructed. The present application innovatively optimizes the source of L-lactate dehydrogenase L-LDH, knocks out L-lactate dehydrogenase CYB2 and branched-chain-2-oxo acid decarboxylase THI3, overexpresses pyruvate kinase CDC19 and H(+)-ATPase PMA2, and makes the L-lactic acid production of Saccharomyces cerevisiae increase to 33.45 g / L.

The present application relates to the use of glial fibrillary acidic protein and lactate dehydrogenase A subtype in the preparation of a kit for diagnosing craniocerebral trauma, and provides the use of glial fibrillary acidic protein and lactate dehydrogenase A subtype as a combined indicator in the preparation of a diagnostic kit for diagnosing craniocerebral trauma. The present application also provides the use of reagents for detecting glial fibrillary acidic protein and lactate dehydrogenase A subtype in the preparation of a diagnostic kit for diagnosing craniocerebral trauma. The present application also provides the use of anti-glial fibrillary acidic protein monoclonal antibody and anti-lactate dehydrogenase A subtype monoclonal antibody in the preparation of an immunochromatographic diagnostic kit for diagnosing craniocerebral trauma. The present application simultaneously detects two biomarkers, GFAP and LDHA, in peripheral blood samples, thereby rapidly determining whether craniocerebral injury has occurred, and classifying the severity based on the detection results, to provide a rapid, objective and portable detection means for clinical emergency, pre-hospital emergency and hierarchical management.

The present invention discloses an application of inhibitors of glycolytic pathway in preparing drugs for preventing and treating porcine reproductive and respiratory syndrome virus (PRRSV) infection. The present invention found that the inhibitors of glycolytic pathway can be used to prevent and treat PRRSV infection, especially, oral administration of the lactate dehydrogenase inhibitor, sodium oxamate or Galloflavin, can significantly inhibit PRRSV replication in pigs, and the present invention found a new use of the inhibitors of glycolytic pathway, especially the lactate dehydrogenase inhibitor (sodium oxamate or Galloflavin), as a PRRSV antagonist for the first time. The sodium oxamate and Galloflavin have clear anti-PRRSV medicinal ingredients, are quality controllable, safe and non-toxic, and have a good application prospect in prevention and treatment of PRRSV.

This invention discloses albumin nanoparticles co-loaded with flavin and lactate oxidase, their preparation method, and applications. Using human serum albumin as a carrier, flavin and lactate oxidase are simultaneously encapsulated at a mass ratio of 10:1, with a particle size of 150-180 nm and a polydispersity index of less than 0.2. This invention exerts its anti-hepatocellular carcinoma effect through mechanisms such as reducing lactate levels in the tumor microenvironment, inducing an increase in reactive oxygen species, inhibiting cGAS protein lactation modification, and activating the cGAS-STING signaling pathway. The nanoparticles exhibit high encapsulation efficiency and good stability. The flavin loaded on these nanoparticles can significantly reduce the reduction of pyruvate to lactate by inhibiting lactate dehydrogenase; simultaneously, the lactate oxidase loaded on these nanoparticles catalyzes the dehydrogenation of lactate to pyruvate. In other words, these nanoparticles synergistically regulate lactate metabolism through a two-way regulatory strategy of "reducing source and increasing sink"—"inhibiting lactate production" and "promoting lactate clearance"—significantly enhancing in vitro and in vivo anti-tumor effects, and demonstrating high biosafety.

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the LDHA gene are provided. Compositions and methods for treating subjects having hyperoxaluria are provided.

The application discloses a preparation method of active lactobacillus and application of the active lactobacillus in livestock and poultry feed, and comprises the following steps: S1, inoculating a strain; S2, fermentation culture; and S3, preparing active lactobacillus powder; the application significantly improves the production efficiency and product stability of the active lactobacillus by optimizing the culture medium formula and fermentation process parameters; the soybean meal hydrolysate and corn starch hydrolysis sugar are used as a composite carbon and nitrogen source, and the polysorbate 80 is used to improve the surface permeability of the bacterial body, so that the lactobacillus plantarum can rapidly proliferate in a low-cost culture medium, and a foundation is laid for efficient synthesis of bacteriocin; fumaric acid is used to inhibit the activity of lactate dehydrogenase, metabolic flow is directed to the bacteriocin synthesis path, the accumulation amount of lactic acid is effectively reduced, and the feedback inhibition of the acid metabolite on the bacterial body is avoided; the prepared active lactobacillus powder has excellent thermal stability, and realizes long-acting stability of the antibacterial effect of the feed.

The invention discloses an antibody for resisting falciparum malaria lactate dehydrogenase, and relates to the field of antibodies. The anti-falciparum malaria lactate dehydrogenase antibody disclosed by the invention comprises a heavy chain complementary determining region and a light chain complementary determining region, provides an important raw material source for detection of falciparum malaria lactate dehydrogenase, and has good activity and sensitivity.

To provide alternative treatments for subjects suffering from diseases, disorders, and conditions related to the oxalate pathway. [Solution] The present invention relates to a double-stranded ribonucleic acid (dsRNA) composition that targets the LDHA gene, a method for inhibiting LDHA expression, a method for inhibiting LDHA and HAO1 using such a dsRNA composition, and a method for treating subjects who may benefit from reduced LDHA expression, for example, subjects suffering from diseases, disorders or conditions related to the oxalate pathway.

The invention relates to the technical field of biology, and particularly discloses a preparation method and application of serum exosomes after electroacupuncture, and the method comprises the following steps: establishing a rat myocardial ischemia reperfusion injury model; applying electroacupuncture stimulation with current of 1mA, frequency of 2Hz and sparse and dense waves to'neiguan 'acupoints on two sides of the rat; serum is collected, and exosomes are extracted through a differential centrifugation method and an ultracentrifugation method; identifying form, particle size and surface marker proteins CD9 and CD81 of the extracted exosome by using a transmission electron microscope and a nanoflow detection technology; the exosome can be internalized by H9c2 myocardial cells, the survival rate of hypoxia / reoxygenation damaged myocardial cells is improved, and the levels of lactic dehydrogenase, creatine kinase and creatine kinase isoenzyme in cell supernatant are reduced. According to the scheme provided by the invention, a novel post-acupuncture serum exosome for treating myocardial ischemia reperfusion injury is provided, and the exosome effectively plays an acupuncture-like role in a treatment process, so that an effect of relieving myocardial ischemia reperfusion is achieved.

The invention discloses a Pucurbita pepo polypeptide Nacrein-LP20 capable of resisting skin photoaging as well as preparation and application of the Pucurbita pepo polypeptide Nacrein-LP20, and belongs to the technical field of biological medicines. An in-vitro experiment shows that Nacrein-LP20 has a remarkable protection effect on UVB-induced human immortalized keratinocyte injury, and can be used for dose-dependently improving the cell activity, inhibiting the excessive generation of reactive oxygen in cells, enhancing the activity of superoxide dismutase, catalase and glutathione peroxidase, reducing the content of malondialdehyde and the release of lactic dehydrogenase, and inhibiting the damage of UVB-induced human immortalized keratinocyte injury to the human immortalized keratinocyte injury to the human immortalized keratinocyte injury. And cell migration and repair are promoted. In-vivo experiments prove that in a UVB-induced mouse skin photoaging model, photoaging apparent symptoms such as skin erythema, skin thickening and wrinkles can be effectively improved by locally smearing the Nacrein-LP20, epidermal hyperplasia is relieved, and synthesis and ordered arrangement of corium layer collagenous fibers are promoted.

The invention discloses construction and application of a Kluyveromyces marxianus strain for producing D-lactic acid, and belongs to the technical field of microorganisms. On the basis of a metabolic engineering modification strategy, lactic dehydrogenase from lactobacillus helveticus is integrated while pyruvate decarboxylase is knocked out, and a D-lactic acid high-yield strain named FMME-LA01 is obtained. The yield of the D-lactic acid can reach 140g / L after fermentation is carried out for 72 hours under the optimized condition of a shake flask, the yield of the D-lactic acid can reach 135g / L after fermentation is carried out for 70 hours in a 7.5 L fermentation tank, the optical purity can reach 99% or above, and the strain has good hereditary stability and is suitable for industrial production.

This invention provides a physiological age prediction model that predicts the physiological age of a subject by detecting physical examination indicators. These indicators include measurements of blood cells, glucose metabolism, tumor markers, urine components, anthropometric measurements, lipids, blood components, and tissue function. Preferably, these indicators include one or more selected from the following: glomerular filtration rate (eGFR), cystatin C, serum creatinine (SCr), blood urea nitrogen (BUN), timed up and go, light reaction time, fasting blood glucose (FBG), insulin-like growth factor (IGF), superoxide dismutase (SOD), insulin (INS), albumin (Alb), alkaline phosphatase (ALP), folic acid, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and high-sensitivity C-reactive protein (hs-CRP). More preferably, all of the aforementioned physical examination indicators are included. This invention also provides a physiological age prediction device applying the above-mentioned physiological age prediction model and a computer storage medium.

The application provides a T cell antigen receptor, an immune cell expressing the T cell antigen receptor (TCR), and a preparation method and application thereof. The TCR disclosed by the application can be specifically activated by a viral antigen peptide presenting cell, the release level of extracellular cytokines IFN gamma, IL2 and the lactate dehydrogenase release amount are improved, and target cells are significantly killed.

The invention discloses application of cardamine violifolia polypeptide in preparation of an anti-hypoxia preparation, and belongs to the technical field of biological medicine. The preparation method of the cardamine violifolia polypeptide comprises the following steps: extracting cardamine violifolia protein from cardamine violifolia; fixing the mixed enzyme on a solid-phase carrier to obtain an immobilized enzyme; the mixed enzyme is alkaline protease and neutral protease; the mass ratio of the alkaline protease to the neutral protease is (5-6): 1; performing enzymolysis on the cardamine violifolia protein by using the immobilized enzyme, and performing ultrafiltration after enzymolysis to obtain filtrate, namely the cardamine violifolia polypeptide. The application in an anti-hypoxia preparation comprises the step of improving the activity of cell glutathione peroxidase. The activity of cell lactic dehydrogenase is reduced; the content of malondialdehyde in cells is reduced; the activity of cell superoxide dismutase is improved; the cell activity is improved; the cell oxidation resistance is improved.

The application discloses a Bifidobacterium breve and application thereof, and belongs to the technical field of microorganisms. The Bifidobacterium breve CCFM1310 provided by the application has the functions of improving immune organs, increasing the number of white blood cells in blood, up-regulating the activities of acid phosphatase (ACP) and lactate dehydrogenase (LDH), increasing the contents of immunoglobulin IgA, IgG and IgM in serum, regulating intestinal flora and the like, and can improve the immune capacity of the body by increasing the organ index, non-specific immune response and specific immune response of the body. The strain provided by the application can be used as a daily intake of probiotics to replace drugs for improving the immune capacity of the human body, and can be used as a new choice for treating patients with low immunity.

This invention discloses a Hotan summer apple beverage, its preparation method, and its application, belonging to the field of pharmaceutical technology. The Hotan summer apple beverage of this invention comprises the following components, by weight: 500-1000 parts Hotan summer apple extract, 100-200 parts Hotan red grape extract, 1-2 parts Hotan rose, 0.1-0.5 parts saffron, and 20-60 parts flavoring agent. This Hotan summer apple beverage of this invention can significantly increase the proliferation level of H9C2 cells damaged by oxygen-glucose deprivation, and significantly decrease the expression of the serum myocardial injury marker lactate dehydrogenase (LDH), indicating that the beverage of this invention has a protective effect on cardiomyocytes. Compared with the commonly used inhibitor Acetylcysteine, this Hotan summer apple beverage of this invention is made from ingredients that are both food and medicine, with no side effects from long-term use, making it more suitable for long-term use by patients with chronic diseases. The materials in this beverage are Hotan summer apple, Hotan red grape, Hotan rose, and saffron, which are products of large-scale cultivation, with high yield and low cost. The preparation process is simple, reducing the cost of medication.

The Mogroside extract has the effect of improving the damage of the heat stress boar's reproductive capacity. Research shows that, in the process of heat stress of boar, by adding Mogroside extract in the basic diet, the damage of reproductive capacity caused by heat stress can be effectively improved. The test data shows that the Mogroside extract can significantly improve the sperm density, effective sperm number, sperm motility and reduce the sperm abnormality rate of boar; significantly increase the content of a-glucosidase, lactate dehydrogenase, acrosome enzyme and hyaluronidase in the semen, and increase the concentration of testosterone in the serum, enhance the energy supply, structural integrity, functional maturity and fertilization capacity of sperm. Therefore, the Mogroside extract has the potential for further development in the treatment and prevention of heat stress boar's reproductive capacity damage, and can be used for preparing the medicine for improving the heat stress boar's reproductive capacity, so as to further develop the health care function and medicinal value of Siraitia grosvenorii.